Krishna Ravi, Sudha M, Venkateswarmurthy N, Sambathkumar R


Background: Advent of r-DNA techniques and their application to biology and healthcare system is one of the most exciting eras of scientific history. Objectives: In this review, we discuss about pharmacogenetics, pharmacogenomics, advances, applications, challenges and future perspectives of r-DNA technology. Variability in drug responses is the net result of multiple interacting genes and environmental factors. Conclusion: We found that many technical and conceptual barriers still remain unveil to the world, if the true potential of this field recognize, the genetic disorders will completely disappear and will get a solution for most questionable microbial resistance. It is anticipated that less than 10% of drugs in 10 years from now will be prescribed following a pharmacogenetic test. In future, we need more intensive studies in the areas of pharmacogenomics to identify the targeted gene which is responsible for specific diseases or variable drug response, so the r-DNA technology can easily develop a new drug molecule which can change the gene expression or may modify the targeted gene. Field of pharmacogenomics will lead to new important insights and discoveries that will ultimately lead to the development of new and better drugs and to the rational use of drugs that are already on the market.

Key wordsr-DNA, pharmacogenetics, pharmacogenomics, genetic disorders, gene expression.

Full Text:



World Health Organization. Deaths from NCDs 2012. WHO, Geneva. http://www.who.int/gho/ncd/mortality_morbidity/ncd_total/en/index.html. [Last assessed on 2012 July 31]

World Health Organization. Global Status Report on non-communicable diseases 2010.WHO, Geneva.

Ventola CL. Pharmacogenomics in Clinical Practice. P&T 2011;36(7):412-422.

Penno MB, Dvorchik BH, Vesell E S. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc. Natl. Acad. Sci. U.S.A., 1981;78:5193-6.


Pandey S, Suba N. Recombinant DNA technology and genetic engineering: a safe and effective meaning for production valuable biological. Int J Pharm Sci Rev Res 2010;1(1):1-20.

Cardi T, Stewart CN. Progress of targeted genome modification approaches in higher plants. plant cell rep 2016;35(7):1401–1416. .

Human insulin receives FDA approval. FDA Drug Bull 1982;12:18-19.

Bazan-Peregrino M, SainsonRCA ,Laga R, Carlisle RC, Thoma C, Waters RA et al., Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Ther. 2013;20(8):461–468.

Aneesh TP, Sonal SM, Asha J, Lekshmi C, Subin MZ. Pharmacogenomics: The Right Drug to the Right Person. J Clin Med Res 2009;1(4):191–4.

Venter M. Synthetic promoters: genetic control through cis engineering. Trends Plant Sci. 2007;12(3):118–124.

Liu W, Yuan JS, Stewart C. Advanced genetic tools for plant biotechnology. Nature Rev Genet. 2013;14(11):781–793.

Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013; 15(2):65-77.

Muller AR, Lajic S, Huhtaniemi I. Assisted large fragment insertion by Red/ET-recombination (ALFIRE)—an alternative and enhanced method for large fragment recombining. Nucleic Acids Res 2007;35(10):e78.

Metzger LE, Raetz CR. Purification and characterization of the lipid A disaccharide synthase (LpxB) from Escherichiacoli, a peripheral membrane protein. J Biochem 2009; 48(48):11559–71.

Pennisi E. The CRISPR craze. Science 2013;341(6148):833–6.

Gaj T, Gersbach CA, Barbas CF. ZFN, TALEN and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 2013;31(7):397-405.

Blackburn PR, Campbell JM, Clark KJ, Ekker SC. The CRISPR system--keeping zebrafish gene targeting fresh. Zebrafish 2013;10(1):116-8.

Justyna Z, Monika P, Barbara S, Krzysztof M, Sylwia M, Renata MD. A study of the activity and effectiveness of recombinant fibroblast growth factor (Q40P/S47I/H93G rFGF-1) in anti-aging treatment. PostepyDermatolAlergol 2016;33(1):28–36.

Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering vascularized tissue. Nat Biotechnol 2005;23(7):821-3.

Human insulin receives FDA approval. FDA Drug Bull. 1982;12:18-9.

Bazan-Peregrino M, Sainson RC, Carlisle RC, Thoma C, Waters RA, Arvanitis C, et al. Combining virotherapy and angiotherapy for the treatment of breast cancer. Cancer Gene Ther 2013;20(8):461-8.

Rostami-HA, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007;6(2):140-8.

Jeremy KN, Elaine H, Ian DW. Gut microorganisms, mammalian metabolism and personalized health care. Nature Rev. Microbiol 2005;3:431-8

Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16(2):198-204

Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering vascularized tissue. Nat Biotechnol 2005;23(7):821-3.

Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al., Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006;12(4):401-9.

Fan QR, Hendrickson WA. Structure of human follicle-stimulating hormone in complex with its receptor. Nature. 2005;433(7023):269-77.

Assidi M, Dufort I, Ali A, Hamel M, Algriany O, Dielemann S, Sirard MA. Identification of potential markers of oocyte competence expressed in bovine cumulus cells matured with follicle-stimulating hormone and/or phorbolmyristate acetate in vitro. BiolReprod. 2008;79(2):209-22.

Yanan Z, Ning L, Zhenhua Z, Xiangdong K. Prenatal diagnosis using genetic sequencing and identification of a novel mutation in MMACHC. BMC Med Genet 2015;16:48.

Neus FM, Joan DE, José LC, Esther V, Antonio V. Microbial factories for recombinant pharmaceuticals. Microbial Cell Factories 2009;8:17.

Wesley CV, Lynn KB, Sheila AL, Bruno S, Martin S, Caroline EC. Serodiagnosis of Syphilis: Antibodies to Recombinant Tp0453, Tp92, and Gpd Proteins Are Sensitive and Specific Indicators of Infection by Treponemapallidum. J ClinMicrobiol 2003;41(8):3668–3674.

Vasavirama K. Molecular probes and their applications. Int. J. LifeSc. Bt& Pharm. Res. 2013;2(2):1-42.

Detection of microbial resistance as well as in the identification of pathogen and its antimicrobial resistance. Microbiologyopen 2016;5(1):143–151.

Somnath M, Divya S, Chinmayi P, Hanudatta SA. High yield expression of proteins in E. coli for NMR studies. AdvBiosciBiotechnol 2013;4:751-767.

Thomas SA. Human Immunodeficiency Virus Diagnostic Testing: 30 Years of Evolution. Clin Vaccine Immuno 2016;23(4):249-253.

Tao L, Peng L, Berntsson RP, Liu SM, Park S, Yu F, et al. Engineered botulinum neurotoxin B with improved efficacy for targeting human receptors. Nat Commun. 2017;8(1):53.

Mahmut A, Levent Y. Successful Treatment with Etanercept of Rheumatoid Arthritis Occurring in a Patient with Familial Mediterranean Fever. Turk J Phys Med Rehab 2014;60:69-71.

Food and drug administration (USA). Highlights of prescribing information. 2016. https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM489301.pdf.

Food and drug administration (USA). FDA Product information Intron: interferon alfa-2b, recombinant. Available fromhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2014/103132s5190lbl.pdf

Food and drug administration (USA). FDA Product label information about recombivax. http://www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf

Food and drug administration (USA). Highlights of prescribing information 2016 issue5.https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM503560.pdf.

Corey KR, Nusinersen. Novel Drug Approvals for 2017; An antisense oligonucleotide drug for spinal muscular atrophy. ‎Nat Neurosci 2017;20:497–499.

Yang CL, Chilvers M, Montgomery M, Nolan SJ. Dornasealfa for cystic fibrosis. PaediatrRespir Rev 2017;21:65–67.

Alves MT, Vilaça SS, CarvalhoMd, Fernandes AP, Dusse LM, Gomes KB. Resistance of dialyzed patients to erythropoietin. Rev Bras HematolHemoter. 2015;37(3):190–7.

Hermann G. Preclinical characterization and clinical development of ILARISW (canakinumab) for the treatment of autoinflammatory diseases. CurrOpinChemBiol 2016;32:1–9.

Lloyd HK, Anthony TR. Immunomodulatory activity of interferon-beta. Ann ClinTranslNeurol 2014; 1(8):622–631.

Kanakeswary K, Anthony JB, Yong S, Peter BN, Jane PJ, Gavin JP. Interleukin-1 Receptor Antagonist Protects against Lipopolysaccharide Induced Diaphragm Weakness in Preterm Lambs. PLoS One. 2015; 10(4): e0124390.

Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017.doi: 10.1056/NEJMoa1703068.

Linda L, Ellinor K, Andy TL, Katrin FN, Antonio DG, Rachel AR, et al. Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection. Nat Commun 2016;7:12616. doi: 10.1038/ncomms12616.

Food and drug administration (USA) https://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM561316.pdf.



Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, et al. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2015;373(15):1418-28.




Mani D, Chitranjan K. Biotechnological advances in bioremediation of heavy metals contaminated ecosystems: an overview with special reference to phytoremediation. Int. J. Environ. Sci. Technol 2014; 11:843–872.

Guangyou D, Dirk W. The Roles of Post-translational Modifications in the Context of Protein Interaction Networks. PLoSComput Biol. 2015; 11(2):e1004049.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.